论文部分内容阅读
目的:评价阿替普酶静脉溶栓联合尤瑞克林治疗急性脑梗死的神经功能恢复情况。方法:2013阿年1月-2014年12月收住院的急性脑梗死患者200例,随机按1∶1分为阿替普酶静脉溶栓联合尤瑞克林治疗组(简称:联合治疗组)100例,阿替普酶静脉溶栓对照组100例。所有患者均给予阿替普酶(0.9mg/kg)静脉溶栓,联合治疗组在溶栓后,给予静滴尤瑞克林(0.15PNA U/d),持续7天,治疗中禁用血管紧张素转化酶抑制剂,治疗前、溶栓后第7天,随诊90天,采用用美国国立卫生神功能缺损评分(NHISS)和日常生活能力评分(BI)评价神经功能恢复情况。结果:联合治疗组患者7天和90天的NHISS评分明显低于对照组患者(t=2.389,2.698;P<0.05)。BI评分明显高于对照组(t=0.830,2.679,P<0.05)。结论:阿替普酶静脉溶栓联合尤瑞克林治疗急性脑梗死可促进神经功能恢复,提高患者脑梗死后的生活质量,并且,是安全的。
OBJECTIVE: To evaluate the neurological recovery of acute cerebral infarction treated with intravenous thrombolytic therapy of Altreplase combined with uracil. Methods: A total of 200 acute cerebral infarction patients admitted to hospital from January to December in 2014 were randomized into 1: 1 group to receive intravenous thrombolysis combined with verapamil (the combination therapy group) 100 cases, Alteplase intravenous thrombolysis control group of 100 cases. All patients received intravenous thrombolytic therapy with alteplase (0.9 mg / kg). Patients in the combination group received intravenous erilecin (0.15 PNA U / d) after thrombolysis for 7 days, with vasoconstriction disabled Invertase inhibitor, before treatment, 7 days after thrombolysis, 90 days follow-up, neurological recovery was assessed using NHIS and BI. Results: The NHISS scores at 7 and 90 days in the combination therapy group were significantly lower than those in the control group (t = 2.389 and 2.698; P <0.05). BI score was significantly higher than the control group (t = 0.830,2.679, P <0.05). Conclusion: The combination of intravenous infusion of alteplase and uracil for the treatment of acute cerebral infarction can promote the recovery of neurological function, improve the quality of life after cerebral infarction, and is safe.